Quick Takeaways
- Opaleye Management Inc. filed SCHEDULE 13G for Karyopharm Therapeutics Inc. Common Stock, no par value (KPTI).
- Disclosed ownership: 9.5%.
- Date of event: 10 Oct 2025.
Opaleye Management Inc. - 10 Oct 2025 SCHEDULE 13G Report for Karyopharm Therapeutics Inc. Common Stock, no par value (KPTI)
- Filing Manager
- Opaleye Management Inc.
- Reporting Manager
- Opaleye Management Inc.
- Symbol
- KPTI
- Shares outstanding
- 16,550,654 shares
- Disclosed Ownership
- 1,569,002 shares
- Ownership
- 9.5%
- Form type
- SCHEDULE 13G
- Filing time
- 17 Oct 2025, 16:05:17 UTC
- Date of event
- 10 Oct 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Opaleye Management Inc. disclosed 9.5% ownership in Karyopharm Therapeutics Inc. Common Stock, no par value (KPTI) on 10 Oct 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Oct 2025, 16:05.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 9.5% | 1,569,002 | 0 | 1,569,002 | /s/ James Silverman | President | |
| Opaleye, L.P. | 9.5% | 1,569,002 | 0 | 1,569,002 | /s/ James Silverman | General Partner | |
| James Silverman | 9.5% | 1,569,002 | 0 | 1,569,002 | /s/ James Silverman | Individually |